The  gap between your cholesterol and your actual risk

Cholesterol is a raw material. The body uses it to build cell membranes, produce hormones, and synthesize vitamin D. The concern with LDL specifically is that when it accumulates in the walls of arteries, it can contribute to plaque formation over time. Plaque narrows arteries and increases the risk of obstruction.

But here's the clinical reality: some people with elevated LDL develop significant plaque. Others with the same numbers never do. The difference comes down to factors that standard cholesterol testing doesn't measure, including whether oxidation and inflammation are present at the arterial wall, what the LDL particle size looks like, and whether plaque has actually begun to accumulate.

The markers that help answer those questions include ApoA, ApoB, and high-sensitivity CRP. These are advanced cardiovascular markers that tell a more complete story about lipid behavior and inflammatory burden. They're not part of a standard annual panel. They have to be ordered separately, and most conventional providers don't order them unless something else has already flagged a concern.

Even those markers, though, don't tell you whether plaque is actually present. They tell you about risk factors. The test that tells you what's happening inside your arteries is different.

What Cleerly actually shows you

Cleerly is an AI-powered coronary CT angiography that does something a standard cholesterol panel, and even most imaging, can't: it looks directly inside the coronary arteries and identifies both calcified and soft plaque, tells you which vessels are involved, and quantifies the extent.

That distinction between hard and soft plaque matters clinically. Calcified plaque is older and more stable. Soft plaque is earlier-stage, and because it hasn't yet hardened, it can be more vulnerable. Standard cardiovascular imaging misses soft plaque entirely. Cleerly catches both.

The result isn't a risk estimate. It's an actual answer. Either there is plaque in your arteries, or there isn't. If there is, you can see where, how much, and what type. That information changes what comes next in a way that a cholesterol number alone never can.

The test runs around $1,000 and is not covered by insurance for most people. That's a real barrier, and it's worth naming directly. But for someone who has elevated LDL, a family history of cardiovascular disease, or postmenopausal risk factors and wants to know with certainty what's happening in their arteries, it's the test that closes the question. You do it once and you have a clear baseline to work from.

Why this matters more than the LDL number

The conventional approach to elevated LDL is to treat the number. Statins lower LDL. The assumption is that lowering LDL lowers risk.

That's true at the population level and in patients with confirmed cardiovascular disease. It's less clear in patients who have elevated LDL but no other risk markers and no evidence of plaque accumulation. Statins carry real side effects, including muscle pain, fatigue, and effects on blood glucose, and they suppress the whole cholesterol system rather than targeting a specific dysfunction.

The functional medicine question isn't "should we lower this number?" It's "what is actually happening in this person's cardiovascular system, and what does that picture tell us about what to do?"

If Cleerly shows no plaque, the priority shifts to optimizing the metabolic, inflammatory, and lifestyle picture: nutrition, sleep, stress, exercise, and the hormonal environment that influences cardiovascular risk. For postmenopausal women specifically, estrogen plays a protective role in cardiovascular health, and the hormone picture is always part of the conversation.

If plaque is present, the clinical response becomes more targeted, and specific supplements, statins when indicated, and more aggressive lifestyle work are all on the table. But that decision is made from a position of knowing, not estimating.

The conversation most providers skip

If your LDL is elevated and you've been told to watch your diet and come back in three months, that advice isn't wrong. But it's also not a plan.

A plan includes understanding your inflammatory markers, your ApoB, your blood glucose and insulin picture, your family history in the context of your specific labs, and ideally some direct information about whether plaque is present in your arteries.

It includes understanding that for women in perimenopause and menopause, cardiovascular risk increases as estrogen declines, and that hormone therapy, when built on a comprehensive clinical baseline, may play a role in supporting cardiovascular protection as part of a broader picture.

It includes knowing that if you don't have plaque, the goal is to keep it that way through the full picture of lifestyle, metabolic health, and hormonal balance. And if you do, the goal is to understand the extent, the type, and the most effective path to slowing any progression.

A number on a lipid panel starts the conversation. It doesn't end it.